Anavex Life Sciences Releases Promising Results for Parkinson’s Disease Treatment
New York, March 30, 2023 – Anavex Life Sciences Corp. (Nasdaq: AVXL), a clinical-stage biopharmaceutical
company, has announced promising results from its 48-week open-label extension
Phase 2 study of ANAVEX®2-73 (blarcamesine) in patients with Parkinson’s
disease dementia. The study, which successfully met both primary and secondary
objectives, revealed consistent clinical improvements in patients’ symptoms over the study period.
ANAVEX®2-73, an oral small-molecule targeting the sigma-1 receptor, demonstrated safety and
tolerability consistent with its known profile. Additionally, the treatment
showed positive effects across all efficacy endpoints, including the Movement
Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) and the
Montreal Cognitive Assessment (MoCA).
Anavex’s study involved participants who had completed a previous double-blind placebo-controlled Phase 2
trial. During the extension phase, patients were allowed to continue their
stable regimen of anti-Parkinson’s disease medications while receiving
ANAVEX®2-73. Results indicated that clinical scores worsened during a ‘drug
holiday’ period, highlighting the significant improvements observed when ANAVEX®2-73 treatment resumed.
Dr. Christopher U Missling, President & CEO of Anavex Life Sciences, stated, “It is
encouraging that patients’ clinical symptoms improved consistently during the
extension phase under active ANAVEX®2-73 treatment.” This highlights the
potential of ANAVEX®2-73 to address the critical unmet needs in Parkinson’s treatment.
Moreover, Anavex Life Sciences continues to support participants beyond the 48-week study through
a compassionate use program, reflecting the company’s commitment to patient
care. This ongoing effort aligns with a research grant awarded by The Michael
J. Fox Foundation for an imaging-focused Parkinson’s disease clinical trial
involving ANAVEX®2-73.
Anavex Life Sciences remains focused on developing innovative therapies for
neurodegenerative and neurodevelopmental disorders. More information about
their ongoing research and development efforts can be found at www.anavex.com.
See related link for more information.
More about Anavex on https://www.bloomberg.com/profile/company/AVXL:US